The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2010-01-01 / J. Virol. 2010 Jan;84(1):639-46Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
/in Colorectal Cancer, Hyperthermia, International Publications /von 2010-01-01 / Int J Hyperthermia 2010;26(2):108-17Tumor antigen presentation by dendritic cells
/in Dendritic Cells, International Publications /von 2010-01-01 / Crit. Rev. Immunol. 2010;30(4):345-86Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
/in Glioblastoma, Hyperthermia, International Publications /von 2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-405Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2009-12-15 / Clin. Cancer Res. 2009 Dec;15(24):7726-7736Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
/in Dendritic Cells, International Publications /von 2009-12-01 / Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):328-43Heat shock proteins and immunity: application of hyperthermia for immunomodulation
/in Hyperthermia, International Publications /von 2009-12-01 / Int J Hyperthermia 2009 Dec;25(8):610-6The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-41A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
/in International Publications, Prostate Cancer /von 2009-12-01 / Expert Opin Biol Ther 2009 Dec;9(12):1565-75IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de